

# Cutaneous B-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management

Alexandra C. Hristov<sup>1</sup> | Trilokraj Tejasvi<sup>2</sup> | Ryan A. Wilcox<sup>1,3</sup> 

<sup>1</sup>Departments of Pathology and Dermatology, University of Michigan, Ann Arbor, Michigan

<sup>2</sup>Department of Dermatology, University of Michigan, Ann Arbor, Michigan

<sup>3</sup>Division of Hematology/Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan

## Correspondence

Ryan A. Wilcox, Division of Hematology/Oncology, University of Michigan Cancer Center, 1500 E. Medical Center Drive, Room 4310 CC, Ann Arbor, MI 48109-5948.  
Email: rywilcox@med.umich.edu

## Abstract

**Disease Overview:** Approximately one-fourth of primary cutaneous lymphomas are B-cell derived and are generally classified into three distinct subgroups: primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, LT).

**Diagnosis:** Diagnosis and disease classification is based on histopathologic review and immunohistochemical staining of an appropriate skin biopsy. Pathologic review and an appropriate staging evaluation are necessary to distinguish primary cutaneous B-cell lymphomas from systemic B-cell lymphomas with secondary skin involvement.

**Risk-Stratification:** Disease histopathology remains the most important prognostic determinant in primary cutaneous B-cell lymphomas. Both PCFCL and PCMZL are indolent lymphomas that infrequently disseminate to extracutaneous sites and are associated with 5-year survival rates that exceed 95%. In contrast, PCDLBCL, LT is an aggressive lymphoma with an inferior prognosis.

**Risk-Adapted Therapy:** Both PCFCL and PCMZL patients with solitary or relatively few skin lesions may be effectively managed with local radiation therapy. While single-agent rituximab may be employed for patients with more widespread skin involvement, multi-agent chemotherapy is rarely appropriate. In contrast, management of patients with PCDLBCL, LT is comparable to the management of patients with systemic DLBCL.

## 1 | DISEASE OVERVIEW

Primary cutaneous lymphomas are a heterogeneous group of extranodal non-Hodgkin lymphomas, approximately 25% of which are B-cell derived and are classified into three major entities in the 2018 World Health Organization (WHO)-European Organization for Research and Treatment of Cancer (EORTC) joint classification: primary cutaneous follicle-center lymphoma (PCFCL), primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, LT), and primary cutaneous marginal zone lymphoma (PCMZL).<sup>1</sup> The incidence of cutaneous B-cell lymphomas (CBCL) has been increasing and is currently  $\approx$ 4 per million persons, based on Surveillance, Epidemiology, and End Results (SEER) registry data, with the highest incidence rates being

reported among males, non-Hispanic whites, and adults over the age of 50.<sup>2,3</sup>

## 2 | DIAGNOSIS

Diagnosis and classification of a CBCL requires an incisional, excisional or 4-6 mm punch biopsy, which includes reticular dermis and subcutaneous fat for morphologic and immunohistochemical analysis, and an appropriate staging evaluation to exclude systemic disease.<sup>4</sup> The use of appropriate immunohistochemical stains (eg, for CD5, cyclin D1) may also aid in distinguishing CBCL from secondary skin involvement by a systemic lymphoma.

## 2.1 | Primary cutaneous follicle center lymphoma

PCFCL commonly present as a solitary purple to pink colored papule (often biopsied to rule out a non-melanoma skin cancer) or as multiple papules, plaques or tumors with a rim of peripheral erythema occurring on the forehead, neck and upper back in middle-aged adults. While grouped lesions may be observed, multifocal disease is less common, as are less common presentations, including rhinophyma and scarring alopecia with tumid pink plaques. Dermoscopy may help differentiate these cutaneous lymphomas from more common non-melanoma skin cancers.<sup>5</sup> Histopathologically, PCFCL are characterized by a follicular, diffuse, or mixed growth pattern comprised of large centrocytes and variable centroblasts derived from germinal-center B cells.<sup>6-8</sup> In contrast to systemic follicular lymphomas, the majority of PCFCL do not harbor the t(14;18) translocation involving the *bcl-2* locus, and do not strongly express *bcl-2* by immunohistochemistry, although expression may be observed in a minority of cases.<sup>9-12</sup> Strong expression of *bcl-2* and CD10 may suggest secondary cutaneous involvement by follicular lymphoma. PCFCLs express *bcl-6*, variably express CD10, and are *MUM-1/IRF-4*, *FOXP1* and IgM negative, consistent with their origin from germinal-center B cells.

## 2.2 | Primary cutaneous diffuse large B-cell lymphoma, leg type

PCDLBCL, leg type commonly affects elderly women and presents with rapidly progressive red brown to blue tumors involving either one or both lower legs.<sup>12,13</sup> Tumors may be ulcerated, and larger tumors may be surrounded by smaller satellite lesions. Less common presentations include verrucous and multicolored nodules. Approximately 10%-15% of cases may involve other cutaneous sites apart from the lower legs, and extracutaneous dissemination is common.<sup>12</sup> These lymphomas are characterized by diffuse sheets of centroblasts and immunoblasts that spare the epidermis, but frequently extend deep into the dermis and subcutaneous tissue. In contrast to PCFCL, lymphoma cells highly express *bcl-2*, likely due to gene amplification,<sup>14,15</sup> as t(14;18) is not observed in PCDLBCL, LT. Dual expression of both *bcl-2* and *c-myc* is common, and is associated with inferior overall survival compared with the minority of PCDLBCL, LT that do not express *c-myc*.<sup>15</sup> Thus *c-myc* translocations (and "double hits") are rare among PCDLBCL, LT.<sup>15</sup> Most cases are *MUM-1/IRF-4*, *FOXP1*, IgM and *bcl-6* positive, CD10 negative, and have a gene expression profile resembling activated B cells.<sup>8</sup> Perhaps not surprisingly, the genetic landscape observed in PCDLBCL, LT is similar to that observed in activated B-cell-type diffuse large B-cell lymphoma (ABC-DLBCL), with NF- $\kappa$ B-activating mutations being observed in *CD79B*, *CARD11*, and *MYD88*.<sup>16-19</sup> Of these, somatic *MYD88*<sup>L265P</sup> mutations appear most common with a prevalence of  $\approx 75\%$ .<sup>15,17-19</sup> Loss of *CDKN2A* has also been identified in a large number of DLBCL-LT patients.<sup>20</sup> Despite the use of somatically hypermutated immunoglobulin heavy-chain variable (IGHV) regions, Staphylococcal superantigen binding sites within the IGHV are preserved, thus implicating

superantigen-dependent B-cell receptor signaling in disease pathogenesis.<sup>21</sup>

## 2.3 | Primary cutaneous marginal zone lymphoma

Patients with PCMZL frequently present with solitary asymptomatic pink papule on the trunk, arm and head and neck area, or as red brown multifocal papules, plaques or nodules involving the trunk and arms. While an association with *Borrelia burgdorferi* has been observed in Europe, a similar association has not been observed in cases from the United States.<sup>22-25</sup> Primary cutaneous marginal zone lymphoma are composed of a variably mixed infiltrate of small, "centrocyte-like" marginal zone B cells, monocytoid B cells, lymphoplasmacytic cells, plasma cells, cells resembling centroblasts and immunoblasts, and reactive T cells. Marginal zone B cells characteristically express *bcl-2* and may express CD43, but lack *bcl-6*, CD10, CD5 and CD23 expression. Recently, two groups of PCMZL have been identified.<sup>1,26-28</sup> The majority of PCMZL express class-switched immunoglobulin and show an indolent course; some have recommended that this type of PCMZL should be considered a lymphoproliferative disorder to reflect its clinical and histopathologic overlap with atypical reactive B-cell infiltrates (pseudo B-cell lymphomas). A second group expresses IgM and shows a behavior similar to extracutaneous extranodal marginal zone lymphomas, with frequent recurrences and extracutaneous spread.

## 3 | RISK STRATIFICATION

The International Society for Cutaneous Lymphomas (ISCL) and EORTC recently proposed staging recommendations for cutaneous lymphomas other than mycosis fungoides and Sézary syndrome.<sup>4</sup> Staging should include a history, physical examination, and imaging (either CT, PET, or increasingly PET/CT) of the chest, abdomen, pelvis, and neck (in cases with involvement of the head or neck). A bone marrow biopsy and aspirate should be performed in cases of PCDLBCL, LT. The joint ISCL/EORTC does not endorse routine bone marrow examination in cases of PCFCL or PCMZL, although approximately 10% of patients with follicle center lymphomas have bone marrow involvement and in most of these patients, the bone marrow is the only site of extracutaneous disease.<sup>29</sup> Bone marrow involvement was associated with significantly inferior disease-specific survival. While the TNM staging classification describes the extent of disease, staging in CBCL is of limited prognostic value, as the disease histopathology is the major determinant in risk-stratification. This is highlighted by a population-based study which identified histopathology and the site of skin involvement as important prognostic factors.<sup>30</sup> In contrast, the International Extranodal Lymphoma Study Group identified three independent prognostic factors (ie, elevated LDH, >2 skin lesions, and nodular lesions) among patients with PCFCL and PCMZL. These factors were combined to form the cutaneous lymphoma international prognostic index (CLIPi). The absence of any adverse prognostic factor was associated with a 5-year progression-free survival of 91%. In

contrast, the presence of two or three adverse prognostic factors was associated with a 5-year progression-free survival of 48%. As the vast majority of relapses were confined to the skin, the CLIP1 was unable to risk-stratify patients by overall survival. The presence of multiple skin lesions was associated with inferior disease-free survival in a European series,<sup>31</sup> but was not associated with disease-free survival in a large North American series.<sup>32</sup> The most important factor for risk-stratification among the cutaneous B-cell lymphomas remains the histopathologic classification. Indolent CBCL (PCFCL and PCMZL) are associated with 5-year disease-specific survival  $\geq 95\%$ ,<sup>6,32</sup> though PCMZL with IgM expression have been associated with a more aggressive course. Differences in growth pattern, the density of centroblasts, and cytogenetic findings do not appear to provide meaningful prognostic information in PCFCL. Although numbers are limited, some authors have found that PCFCL occurring on the leg have a worse prognosis and are more likely to have an immunophenotype that overlaps with DLBCL-LT<sup>12,33</sup> These authors suggest that consideration should be given to systemic chemotherapy in such patients. In contrast, PCDLBCL, LT is associated with a 5-year disease-specific survival of approximately 50%, and dual *bcl-2* and *c-myc* expression<sup>6,15,17,34</sup> and loss of *CDKN2A* are associated with inferior survival.<sup>20</sup> The presence of a somatic *MYD88*<sup>L265P</sup> mutation is also associated with inferior disease-specific and overall survival.<sup>17</sup> In contrast to patients presenting with only a single tumor, involvement of multiple sites, on one or both legs, is associated with a significantly inferior disease-specific survival.<sup>35</sup>

## 4 | TREATMENT

As no randomized controlled trials are available, treatment recommendations for CBCL are largely based on small retrospective studies and institutional experience. The EORTC and ISCL have published consensus treatment recommendations that are consistent with NCCN guidelines.<sup>36</sup> In most cases, optimal patient management requires a multidisciplinary approach, including dermatology, medical oncology and radiation oncology.

### 4.1 | Primary cutaneous follicle center lymphoma

For patients with solitary lesions, low-dose radiation therapy is safe and highly effective, with a complete remission rate approaching 100%. Radiation does not appear inferior to multi-agent chemotherapy among patients with multiple lesions that can be included in multiple radiation fields.<sup>37</sup> In a large North American series, the rate of local control for indolent CBCL with radiation alone was 98%.<sup>32</sup> In the same series, a local recurrence requiring radiation therapy was observed in 25% of patients who had undergone surgical excision alone. Reserving radiation until disease recurrence did not appear to compromise disease-specific or overall survival.<sup>32</sup> Therefore, complete excision alone, deferring radiation until disease recurrence, is also reasonable. Intralesional [eg, corticosteroids or rituximab<sup>38</sup>] or topical therapies including corticosteroids,

nitrogen mustard and bexarotene may also be considered.<sup>39,40</sup> While radiation therapy is generally recommended for patients with a solitary lesion, radiation therapy or observation (ie, "watch and wait") are reasonable options for those patients with multiple lesions. Rarely, patients with PCFCL may show a locally aggressive course<sup>41,42</sup> and some have suggested the possibility of transformation to DLBCL,<sup>43,44</sup> suggesting that "watch and wait" patients require close clinical follow-up. Patients with more extensive skin involvement are effectively managed with single-agent rituximab.<sup>36</sup> Approximately one-third of patients may relapse following either radiation or single-agent rituximab, but relapses are usually confined to the skin and are approached in a manner similar to that described for the initial management of PCFCL.

### 4.2 | Primary cutaneous marginal zone lymphoma

Patients with PCMZL are approached in a manner analogous to that described in the initial management of PCFCL. Radiation therapy or surgical excision are associated with high response rates for patients with a single or few lesions.<sup>36</sup> Those with more widespread skin involvement may be observed. Once symptomatic, culprit lesions may be irradiated or surgically excised.<sup>45</sup> As for PCFCL, single-agent rituximab may be utilized in patients with symptomatic, widespread skin lesions. An initial trial of antibiotics for those with *B. burgdorferi*-associated PCMZL has been recommended,<sup>46</sup> but is less relevant for North American patients.

### 4.3 | Primary cutaneous diffuse large B-cell lymphoma, leg type

As previously noted, the natural history of PCDLBCL, LT more closely resembles that of systemic DLBCL. Therefore, R-CHOP (with or without radiation therapy) is utilized in these patients. While few reports are available in the literature, the use of R-CHOP in these patients is associated with disease-free survival rates rivaling those reported for patients with high-risk systemic DLBCL.<sup>12,13,32,36</sup> Most patients present with disease confined to the leg(s) and are managed like patients with limited stage systemic DLBCL with R-CHOP and involved field radiation therapy. The management of relapsed disease is comparable to that for relapsed systemic ABC-DLBCL (eg, lenalidomide,<sup>47</sup> ibrutinib<sup>48</sup>). In a small phase II study ( $n = 19$ ), the 6-month overall response rate with single-agent lenalidomide in relapsed/refractory PCDLBCL, LT was 26%, but was significantly higher in patients without the *MYD88*<sup>L265P</sup> mutation.<sup>49</sup>

#### CONFLICT OF INTEREST

The authors declare no conflict of interest with the content of this paper.

#### DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analyzed in this study

## ORCID

Ryan A. Wilcox  <https://orcid.org/0000-0002-6420-0760>

## REFERENCES

1. Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. *Blood*. 2019;133:1703-1714.
2. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. *Blood*. 2009;113:5064-5073.
3. Korgavkar K, Weinstock MA. Changing incidence trends of cutaneous B-cell lymphoma. *J Invest Dermatol*. 2014;134:840-842.
4. Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). *Blood*. 2007;110:479-484.
5. Geller S, Marghoob AA, Scope A, Braun RP, Myskowski PL. Dermoscopy and the diagnosis of primary cutaneous B-cell lymphoma. *J Eur Acad Dermatol Venereol*. 2018;32:53-56.
6. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. *Blood*. 2005;105:3768-3785.
7. Gellrich S, Rutz S, Golembowski S, et al. Primary cutaneous follicle center cell lymphomas and large B cell lymphomas of the leg descend from germinal center cells. A single cell polymerase chain reaction analysis. *J Invest Dermatol*. 2001;117:1512-1520.
8. Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. *Blood*. 2005;105:3671-3678.
9. Cerroni L, Kerl H. Immunoreactivity for bcl-2 protein in cutaneous lymphomas and lymphoid hyperplasias. *J Cutaneous Pathol*. 1995;22:476-478.
10. Cerroni L, Volkenandt M, Rieger E, Soyer HP, Kerl H. bcl-2 protein expression and correlation with the interchromosomal 14;18 translocation in cutaneous lymphomas and pseudolymphomas. *J Invest Dermatol*. 1994;102:231-235.
11. Cerroni L, Arzberger E, Putz B, et al. Primary cutaneous follicle center cell lymphoma with follicular growth pattern. *Blood*. 2000;95:3922-3928.
12. Senff NJ, Hoefnagel JJ, Jansen PM, et al. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. *J Clin Oncol*. 2007;25:1581-1587.
13. Grange F, Beylot-Barry M, Courville P, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. *Arch Dermatol*. 2007;143:1144-1150.
14. Mao X, Lillington D, Child F, Russell-Jones R, Young B, Whittaker S. Comparative genomic hybridization analysis of primary cutaneous B-cell lymphomas: identification of common genomic alterations in disease pathogenesis. *Genes Chromosomes Cancer*. 2002;35:144-155.
15. Menguy S, Frison E, Prochazkova-Carlotti M, et al. Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas. *Mod Pathol*. 2018;31:1332-1342.
16. Koens L, Zoutman WH, Ngarmliertsirichai P, et al. Nuclear factor-kappaB pathway-activating gene aberrancies in primary cutaneous large B-cell lymphoma, leg type. *J Invest Dermatol*. 2014;134:290-292.
17. Pham-Ledard A, Beylot-Barry M, Barbe C, et al. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type. *JAMA Dermatol*. 2014;150:1173-1179.
18. Menguy S, Gros A, Pham-Ledard A, et al. MYD88 Somatic mutation is a diagnostic criterion in primary cutaneous large B-cell lymphoma. *J Invest Dermatol*. 2016;136:1741-1744.
19. Mareschal S, Pham-Ledard A, Viailly PJ, et al. Identification of somatic mutations in primary cutaneous diffuse large B-cell lymphoma, leg type by massive parallel sequencing. *J Invest Dermatol*. 2017;137:1984-1994.
20. Senff NJ, Zoutman WH, Vermeer MH, et al. Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type. *J Invest Dermatol*. 2009;129:1149-1155.
21. Pham-Ledard A, Prochazkova-Carlotti M, Deveza M, et al. Molecular analysis of immunoglobulin variable genes supports a germinal center experienced normal counterpart in primary cutaneous diffuse large B-cell lymphoma, leg-type. *J Dermatol Sci*. 2017;88:238-246.
22. Cerroni L, Zochling N, Putz B, Kerl H. Infection by *Borrelia burgdorferi* and cutaneous B-cell lymphoma. *J Cutaneous Pathol*. 1997;24:457-461.
23. Goodlad JR, Davidson MM, Hollowood K, Batstone P, Ho-Yen DO. *Borrelia burgdorferi*-associated cutaneous marginal zone lymphoma: a clinicopathological study of two cases illustrating the temporal progression of B. burgdorferi-associated B-cell proliferation in the skin. *Histopathology*. 2000;37:501-508.
24. Goodlad JR, Davidson MM, Hollowood K, et al. Primary cutaneous B-cell lymphoma and *Borrelia burgdorferi* infection in patients from the Highlands of Scotland. *Am J Surg Pathol*. 2000;24:1279-1285.
25. Wood GS, Kamath NV, Guitart J, et al. Absence of *Borrelia burgdorferi* DNA in cutaneous B-cell lymphomas from the United States. *J Cutaneous Pathol*. 2001;28:502-507.
26. Carlsen ED, Swerdlow SH, Cook JR, Gibson SE. Class-switched primary cutaneous marginal zone lymphomas are frequently IgG4-positive and have features distinct from IgM-positive cases. *Am J Surg Pathol*. 2019;43:1403-1412.
27. Edinger JT, Kant JA, Swerdlow SH. Cutaneous marginal zone lymphomas have distinctive features and include 2 subsets. *Am J Surg Pathol*. 2010;34:1830-1841.
28. van Maldegem F, van Dijk R, Wormhoudt TA, et al. The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develops in a T-helper type 2 inflammatory environment. *Blood*. 2008;112:3355-3361.
29. Senff NJ, Kluijn-Nelemans HC, Willemze R. Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma. *Br J Haematol*. 2008;142:52-56.
30. Smith BD, Smith GL, Cooper DL, Wilson LD. The cutaneous B-cell lymphoma prognostic index: a novel prognostic index derived from a population-based registry. *J Clin Oncol*. 2005;23:3390-3395.
31. Zinzani PL, Quaglino P, Pimpinelli N, et al. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. *J Clin Oncol*. 2006;24:1376-1382.
32. Hamilton SN, Wai ES, Tan K, Alexander C, Gascoyne RD, Connors JM. Treatment and outcomes in patients with primary cutaneous B-cell lymphoma: the BC Cancer Agency experience. *Int J Radiat Oncol Biol Phys*. 2013;87:719-725.
33. Koens L, Vermeer MH, Willemze R, Jansen PM. IgM expression on paraffin sections distinguishes primary cutaneous large B-cell lymphoma, leg type from primary cutaneous follicle center lymphoma. *Am J Surg Pathol*. 2010;34:1043-1048.
34. Hallermann C, Kaune KM, Gesk S, et al. Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas. *J Invest Dermatol*. 2004;123:213-219.
35. Grange F, Bekkenk MW, Wechsler J, et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. *J Clin Oncol*. 2001;19:3602-3610.

36. Senff NJ, Noordijk EM, Kim YH, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. *Blood*. 2008;112:1600-1609.
37. Bekkenk MW, Vermeer MH, Geerts ML, et al. Treatment of multifocal primary cutaneous B-cell lymphoma: a clinical follow-up study of 29 patients. *J Clin Oncol*. 1999;17:2471-2478.
38. Penate Y, Hernandez-Machin B, Perez-Mendez LI, et al. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma. *Br J Dermatol*. 2012;167:174-179.
39. Perry A, Vincent BJ, Parker SR. Intralesional corticosteroid therapy for primary cutaneous B-cell lymphoma. *Br J Dermatol*. 2010;163:223-225.
40. Coors EA, Schuler G, Von Den Driesch P. Topical imiquimod as treatment for different kinds of cutaneous lymphoma. *Eur J Dermatol*. 2006;16:391-393.
41. Oschlies I, Kohler CW, Szczepanowski M, et al. Spindle-cell variants of primary cutaneous follicle center B-Cell lymphomas are germinal center B-cell lymphomas by gene expression profiling using a formalin-fixed paraffin-embedded specimen. *J Invest Dermatol*. 2017;137:2450-2453.
42. Fierro MT, Marengo F, Novelli M, Fava P, Quaglino P, Bernengo MG. Long-term evolution of an untreated primary cutaneous follicle center lymphoma of the scalp. *Am J Dermatopathol*. 2010;32:91-94.
43. Swerdlow SH, Quintanilla-Martinez L, Willemze R, Kinney MC. Cutaneous B-cell lymphoproliferative disorders: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. *Am J Clin Pathol*. 2013;139:515-535.
44. Tsang HC, Mathew S, Magro CM. An aggressive primary cutaneous follicle center lymphoma with c-MYC translocation and CDKN2A (9p21) deletion: a case report and review of the literature. *Am J Dermatopathol*. 2017;39:e44-e49.
45. Parbhakar S, Cin AD. Primary cutaneous B-cell lymphoma: role of surgery. *Can J Plast Surg*. 2011;19:e12-e14.
46. Dreno B. Standard and new treatments in cutaneous B-cell lymphomas. *J Cutaneous Pathol*. 2006;33(Suppl 1):47-51.
47. Savini P, Lanzi A, Foschi FG, Marano G, Stefanini GF. Lenalidomide monotherapy in relapsed primary cutaneous diffuse large B cell lymphoma-leg type. *Ann Hematol*. 2014;93:333-334.
48. Gupta E, Accurso J, Sluzevich J, Menke DM, Tun HW. Excellent outcome of immunomodulation or Bruton's tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large B-cell lymphoma, leg type. *Rare Tumors*. 2015;7:6067.
49. Beylot-Barry M, Mermin D, Maillard A, et al. A single-arm phase II trial of lenalidomide in relapsing or refractory primary cutaneous large B-cell lymphoma leg-type. *J Invest Dermatol*. 2018;138:1982-1989.

**How to cite this article:** Hristov AC, Tejasvi T, Wilcox RA. Cutaneous B-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management. *Am J Hematol*. 2020;95:1209-1213. <https://doi.org/10.1002/ajh.25970>